What is the term used for the restrictions on Group Purchasing Organizations in the context of 340B?

The term "GPO Prohibition" refers specifically to the restrictions placed on Group Purchasing Organizations (GPOs) concerning the 340B Drug Pricing Program. Under this prohibition, certain covered entities participating in the 340B program are not allowed to utilize GPOs for the acquisition of drugs that they intend to purchase at the discounted 340B price. This regulation is designed to ensure that the benefits of the 340B program are directed solely to eligible entities and not diluted by participation in GPOs, which could potentially offer advantageous pricing but may conflict with the intentions of the 340B discount.

Understanding this terminology is crucial, as it highlights the significance of maintaining compliance with the rules governing the 340B program. Being aware of the GPO prohibition helps healthcare providers navigate their purchasing decisions while ensuring they remain eligible for 340B discounts, ultimately benefiting the underserved populations they serve. The other terms mentioned do not accurately represent this specific restriction or the legal framework surrounding it, making "GPO Prohibition" the precise term used in this context.